News

  • 6 January 2020

    Sonendo®, Inc., a leading dental technology company, announced today that EW Healthcare Partners, a global healthcare growth equity firm, led an $85 million financing for the Company. Other new investors include Redmile Group, ArrowMark Partners, and Broadfin Capital. Other existing investors participating in the round include General Atlantic, Orbimed Advisors LLC, Meritech Capital Partners, CVF LLC, NeoMed Management, Perceptive Advisors, JMR Capital, SEB Private Equity, and Security Pacific Finance.

  • 30 December 2019

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) in combination with ibrutinib (Imbruvica®) for the treatment of Waldenström’s macroglobulinemia (WM), a rare form of non-Hodgkin’s lymphoma. Mavorixafor, X4’s lead therapeutic candidate, is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4.

  • 19 December 2019

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devicesfor the treatment of bladder and bowel dysfunction, today announced that the United States Patent and Trademark Office has issued or allowed Axonics nine U.S. utility patents in 2019, along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

  • 12 December 2019

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that the underwriters of its follow-on public offering exercised in full their option to purchase an additional 750,000 shares of common stock from Axonics at the offering price of $22.00 per share, less underwriting discounts and commissions.

  • 9 December 2019

    Avitide, Inc., the industry leader in the discovery and development of custom affinity purification resins, announces that it has entered into an exclusive license agreement to support the development of one of Gemini Therapeutics’ therapeutic programs.